EP1474528A4 - Procedes de diagnostic du cancer de la prostate, compositions et procedes de criblage de modulateurs du cancer de la prostate - Google Patents

Procedes de diagnostic du cancer de la prostate, compositions et procedes de criblage de modulateurs du cancer de la prostate

Info

Publication number
EP1474528A4
EP1474528A4 EP01983958A EP01983958A EP1474528A4 EP 1474528 A4 EP1474528 A4 EP 1474528A4 EP 01983958 A EP01983958 A EP 01983958A EP 01983958 A EP01983958 A EP 01983958A EP 1474528 A4 EP1474528 A4 EP 1474528A4
Authority
EP
European Patent Office
Prior art keywords
methods
prostate cancer
modulators
diagnosis
screening
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01983958A
Other languages
German (de)
English (en)
Other versions
EP1474528A2 (fr
Inventor
Kurt C Gish
David H Mack
Keith E Wilson
Daniel Afar
Peter Hevezi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Garvan Institute of Medical Research
Cedars Sinai Medical Center
Original Assignee
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/847,046 external-priority patent/US20020068036A1/en
Application filed by Protein Design Labs Inc filed Critical Protein Design Labs Inc
Priority to EP07075380A priority Critical patent/EP1847620A3/fr
Publication of EP1474528A2 publication Critical patent/EP1474528A2/fr
Publication of EP1474528A4 publication Critical patent/EP1474528A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP01983958A 2000-10-13 2001-10-12 Procedes de diagnostic du cancer de la prostate, compositions et procedes de criblage de modulateurs du cancer de la prostate Withdrawn EP1474528A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07075380A EP1847620A3 (fr) 2000-10-13 2001-10-12 Procédé pour le diagnostic du cancer de la prostate, compositions et procédés pour le dépistage de modulateurs du cancer de la prostate

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US687576 1984-12-28
US733288 1985-05-10
US68757600A 2000-10-13 2000-10-13
US73328800A 2000-12-08 2000-12-08
US73374200A 2000-12-08 2000-12-08
US733742 2000-12-08
US26395701P 2001-01-24 2001-01-24
US27679101P 2001-03-16 2001-03-16
US27688801P 2001-03-16 2001-03-16
US276791P 2001-03-16
US276888P 2001-03-16
US28192201P 2001-04-06 2001-04-06
US281922P 2001-04-06
US28621401P 2001-04-24 2001-04-24
US286214P 2001-04-24
US09/847,046 US20020068036A1 (en) 2000-10-13 2001-04-30 Novel methods of diagnosis of prostate cancer and/or breast cancer, compositions, and methods of screening for prostate cancer and /or breast cancer modulators
US847046 2001-04-30
US28858901P 2001-05-04 2001-05-04
US288589P 2001-05-04
PCT/US2001/032045 WO2002030268A2 (fr) 2000-10-13 2001-10-12 Procedes de diagnostic du cancer de la prostate, compositions et procedes de criblage de modulateurs du cancer de la prostate
US263957P 2009-11-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP07075380A Division EP1847620A3 (fr) 2000-10-13 2001-10-12 Procédé pour le diagnostic du cancer de la prostate, compositions et procédés pour le dépistage de modulateurs du cancer de la prostate

Publications (2)

Publication Number Publication Date
EP1474528A2 EP1474528A2 (fr) 2004-11-10
EP1474528A4 true EP1474528A4 (fr) 2006-06-14

Family

ID=27581207

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01983958A Withdrawn EP1474528A4 (fr) 2000-10-13 2001-10-12 Procedes de diagnostic du cancer de la prostate, compositions et procedes de criblage de modulateurs du cancer de la prostate

Country Status (6)

Country Link
EP (1) EP1474528A4 (fr)
JP (1) JP2005506033A (fr)
AU (1) AU2002215345A1 (fr)
CA (1) CA2425569A1 (fr)
MX (1) MXPA03003151A (fr)
WO (1) WO2002030268A2 (fr)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2060630B1 (fr) 1997-04-10 2012-10-24 Stichting Katholieke Universiteit University Medical Centre Nijmegen PCA3, gènes de PCA3, et procédés d'utilisation
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
ES2629442T3 (es) 1998-06-01 2017-08-09 Agensys, Inc. Nuevos antígenos transmembranales en serpentina expresados en cánceres humanos y utilizaciones de los mismos
DE60027027T2 (de) 1999-09-29 2006-11-30 Diagnocure Inc. Pca3 mrna in gutartigen und bösartigen prostatageweben
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
US6790631B1 (en) 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
US20020048777A1 (en) 1999-12-06 2002-04-25 Shujath Ali Method of diagnosing monitoring, staging, imaging and treating prostate cancer
US20090176722A9 (en) 2000-01-28 2009-07-09 Shiv Srivastava Androgen-regulated PMEPA1 gene and polypeptides
US20020187524A1 (en) * 2000-12-15 2002-12-12 Millennium Pharmaceuticals, Inc. 8099, 46455, 54414, 53763, 67076, 67102, 44181, 67084FL, and 67084 alt, human proteins and methods of use thereof
ATE396266T1 (de) * 2000-07-28 2008-06-15 Ulrich Wissenbach Trp8 krebsmarker
EP1337667A2 (fr) 2000-11-16 2003-08-27 Cedars-Sinai Medical Center Etablissement de profil de marqueurs specifiques aux tumeurs pour le diagnostic et le traitement de maladies neoplasiques
AU2002246708A1 (en) 2000-12-15 2002-08-12 Agensys, Inc. Nucleic acid and encoded zinc transporter protein entitled 108p5h8 useful in treatment and detection of cancer
US7118912B2 (en) * 2002-08-26 2006-10-10 Case Western Reserve University Methods and compositions for categorizing patients
US20060035237A1 (en) 2002-08-26 2006-02-16 Markowitz Sanford D Methods and compositions for categorizing patients
US7081516B2 (en) 2002-08-26 2006-07-25 Case Western Reserve University Methods for categorizing patients
WO2002072632A2 (fr) * 2001-03-05 2002-09-19 Aventis Pharma S.A. Acides nucleiques du gene abcc11 humain, vecteurs contenant lesdits acides nucleiques et leurs utilisations
WO2002083921A2 (fr) 2001-04-10 2002-10-24 Agensys, Inc. Acides nucleiques et proteines correspondantes utiles pour la detection et le traitement de divers cancers
US6897024B2 (en) 2001-05-31 2005-05-24 Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
ES2372321T3 (es) 2001-06-20 2012-01-18 Genentech, Inc. Composiciones y métodos para el diagnóstico y tratamiento de un tumor de pulmón.
US20050272120A1 (en) 2001-06-20 2005-12-08 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1499350A4 (fr) * 2001-08-31 2006-02-08 Agensys Inc Acide nucleique et proteine correspondante appelee 205p1b5 utilises dans le traitement et la detection du cancer
ES2532757T3 (es) 2001-09-06 2015-03-31 Agensys, Inc. Ácido nucleico y proteína correspondiente denominados STEAP-1 útiles en el tratamiento y la detección de cáncer
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
JP2005519137A (ja) * 2001-09-17 2005-06-30 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ４６８２８ヒトアシル−ＣｏＡシンセターゼの使用方法
US20030100034A1 (en) * 2001-10-16 2003-05-29 Millennium Pharmaceuticals, Inc. 9136, a human aldehyde dehydrogenase family member and uses therefor
CA2470088A1 (fr) * 2001-12-20 2003-07-03 Tularik Inc. Identification d'un gene amplifie et cible pour une intervention medicamenteuse
US20030235533A1 (en) * 2002-02-19 2003-12-25 Idec Pharmaceuticals Corporation Prostate specific genes and the use thereof in design or therapeutics
WO2005067629A2 (fr) * 2004-01-06 2005-07-28 Avalon Pharmaceuticals Genes lies au cancer en tant que cibles pour la chimiotherapie
US20040162236A1 (en) * 2002-04-01 2004-08-19 John Alsobrook Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1361433A3 (fr) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Méthode de detemination l'efficacité d'une TNF thérapie
WO2003095611A2 (fr) 2002-05-10 2003-11-20 Henry M. Jackson Foundation For The Advancement Of Military Medicine Gene pmepa1 regule par les androgenes et procedes d'utilisation de ce dernier pour inhiber la croissance des cellules cancereuses
DE10234901A1 (de) * 2002-07-26 2004-02-12 Metagen Pharmaceuticals Gmbh Verwendung von am Mrp4 bindenden Substanzen zur Diagnose und Behandlung von Krebserkrankungen
US7408048B2 (en) 2002-08-09 2008-08-05 Melbourne Health Mammalian grainyhead transcription factors
WO2004016733A2 (fr) * 2002-08-16 2004-02-26 Agensys, Inc. Acides nucleiques et proteines correspondantes connues sous 251p5g2 que l'on utilise dans le traitement et la detection de cancers
CA2496781A1 (fr) * 2002-08-26 2004-03-04 Case Western Reserve University Methodes de traitement de patients et d'identification de therapeutique
WO2004053495A1 (fr) * 2002-12-09 2004-06-24 Bayer Healthcare Ag Diagnostic et traitement de maladies associees a la phosphodiesterase 9a1(pde9a1)humaine
CA2513780C (fr) 2003-02-07 2014-12-30 Diagnocure Inc. Procede de detection de cancer de la prostate dans un echantillon
JP2004357702A (ja) * 2003-05-09 2004-12-24 Research Association For Biotechnology 新規蛋白質およびそれをコードするｄｎａ
US7473531B1 (en) 2003-08-08 2009-01-06 Colora Corporation Pancreatic cancer targets and uses thereof
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
KR101438983B1 (ko) 2003-11-06 2014-09-05 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
WO2005083086A2 (fr) * 2004-02-27 2005-09-09 Oncotherapy Science, Inc. L'EphA4 COMME CIBLE THÉRAPEUTIQUE DU PCR ET DU PDACa
AU2004319915B9 (en) 2004-04-22 2011-12-22 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
WO2005106488A2 (fr) * 2004-04-28 2005-11-10 Bayer Healthcare Ag Diagnostics et therapeutique de maladies associees a l'adrenorecepteur beta-2 couple aux proteines g (adrb2)
AU2005249490B2 (en) 2004-06-01 2010-07-29 Genentech, Inc. Antibody drug conjugates and methods
WO2006008003A2 (fr) * 2004-07-23 2006-01-26 Bayer Healthcare Ag Agents diagnostiques et therapeutiques pour pathologies associees au recepteur 1 de peptide intestinal vasoactif (vpac1)
PL1791565T3 (pl) 2004-09-23 2016-10-31 Modyfikowane cysteiną przeciwciała i koniugaty
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
EP1817059A2 (fr) 2004-12-01 2007-08-15 Genentech, Inc. Conjugues medicament anticorps et procedes correspondants
CA2491067A1 (fr) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Rapport entre arnm dans les sediments urinaires ou l'urine en tant que marqueur pronostique du cancer de la prostate
WO2006074914A2 (fr) * 2005-01-13 2006-07-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Helicase d'arn humaine et ses utilisations therapeutiques
ES2459492T3 (es) 2005-02-25 2014-05-09 Oncotherapy Science, Inc. Vacunas de péptidos para cánceres de pulmón que expresan polipéptidos TTK, URLC10 o KOC1
ES2636089T3 (es) 2006-10-27 2017-10-05 Genentech, Inc. Anticuerpos e inmunoconjugados y usos para los mismos
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
CA3006428A1 (fr) * 2007-06-08 2008-12-18 Genentech, Inc. Marqueurs d'expression de gene de resistance tumorale a un traiteme r inhibiteur her2
AU2008296927C1 (en) * 2007-09-06 2015-08-13 Case Western Reserve University Methods for diagnosing and treating cancers
AU2014240339B2 (en) * 2007-10-25 2017-07-13 Toray Industries, Inc. Method for detection of cancer
JP5589274B2 (ja) * 2007-10-25 2014-09-17 東レ株式会社 免疫誘導剤
EP3106873B1 (fr) 2007-10-25 2019-07-17 Toray Industries, Inc. Procédé de détection du cancer
EP2303332B1 (fr) 2008-07-15 2014-12-31 Genentech, Inc. Conjugués de dérivés d anthracycline, procédé de préparation associé et utilisation comme composés antitumoraux
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
TWI543767B (zh) 2008-08-19 2016-08-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
US8470980B2 (en) 2009-09-09 2013-06-25 Centrose, Llc Extracellular targeted drug conjugates
WO2011130598A1 (fr) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazépines et conjugués de celles-ci
RU2636461C2 (ru) * 2010-05-03 2017-11-23 Дженентек, Инк. Композиции и способы для диагностики и лечения опухоли
MX336540B (es) 2010-06-08 2016-01-22 Genentech Inc Conjugados y anticuerpos manipulados geneticamente con cisteina.
CA2816426A1 (fr) 2010-11-17 2012-06-07 Genentech, Inc. Conjugues d'anticorps alaninyl-maytansinol
CA2833212C (fr) 2011-05-12 2020-06-09 Genentech, Inc. Reaction multiple de surveillance du procede lc-ms/ms pour detecter les anticorps therapeutiques dans les echantillons d'animaux par des peptides de signature du cadre
US11135303B2 (en) 2011-10-14 2021-10-05 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2013130093A1 (fr) 2012-03-02 2013-09-06 Genentech, Inc. Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
EP2906297B1 (fr) 2012-10-12 2017-12-06 ADC Therapeutics SA Conjugués anticorps - pyrrolobenzodiazépine
EP2839860B1 (fr) 2012-10-12 2019-05-01 MedImmune Limited Pyrrolobenzodiazépines et ses conjugués
MX364328B (es) 2012-10-12 2019-04-23 Medimmune Ltd Conjugados del anticuerpo pirrolobenzodiazepina.
CN105102003B (zh) 2012-10-12 2019-03-05 Adc疗法责任有限公司 吡咯并苯并二氮杂卓-抗psma抗体结合物
JP6392765B2 (ja) 2012-10-12 2018-09-19 エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ ピロロベンゾジアゼピン−抗体結合体
CA2887895C (fr) 2012-10-12 2019-10-29 Adc Therapeutics Sarl Conjugues d'anticorps cd19-anti-pyrrolobenzodiazepine
WO2014057114A1 (fr) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Conjugués pyrrolobenzodiazepine-anticorps anti-psma
AU2013366493B2 (en) 2012-12-21 2017-08-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2014096365A1 (fr) 2012-12-21 2014-06-26 Spirogen Sàrl Dimères de pyrrolobenzodiazépines asymétriques à utiliser dans le traitement de maladies prolifératives et auto-immunes
KR102057755B1 (ko) 2013-03-13 2019-12-19 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
JP6444902B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びその結合体
BR112015021965B1 (pt) 2013-03-13 2022-05-03 Medimmune Limited Conjugados e compostos de pirrolobenzodiazepinas, composição farmacêutica, uso dos mesmos para o tratamento de uma doença proliferativa e método de síntese dos ditos compostos
CN105209636A (zh) * 2013-03-15 2015-12-30 麦塔马克基因股份有限公司 用于癌症预后的组合物和方法
EA201690195A1 (ru) 2013-08-12 2016-05-31 Дженентек, Инк. Конъюгатные соединения антитело-лекарство на основе димера 1-(хлорметил)-2,3-дигидро-1h-бензо[e]индола и способы применения и лечения
EP3054983B1 (fr) 2013-10-11 2019-03-20 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépines
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
EP3054985B1 (fr) 2013-10-11 2018-12-26 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépine
CA2933557A1 (fr) 2013-12-16 2015-06-25 Genentech, Inc. Composes peptidomimetiques et conjugues anticorps-medicament de ceux-ci
RU2689388C1 (ru) 2013-12-16 2019-05-28 Дженентек, Инк. Пептидомиметические соединения и их конъюгаты антител с лекарственными средствами
CN105828840B (zh) 2013-12-16 2020-08-04 基因泰克公司 1-(氯甲基)-2,3-二氢-1H-苯并[e]吲哚二聚体抗体-药物缀合物化合物及使用和治疗方法
US20150252425A1 (en) * 2014-03-05 2015-09-10 Caldera Health Ltd. Gene expression profiling for the diagnosis of prostate cancer
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EP3191521A2 (fr) 2014-09-12 2017-07-19 F. Hoffmann-La Roche AG Anticorps et conjugués modifiés génétiquement avec de la cystéine
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN106714844B (zh) 2014-09-12 2022-08-05 基因泰克公司 蒽环类二硫化物中间体、抗体-药物缀合物和方法
PE20170905A1 (es) 2014-09-17 2017-07-12 Genentech Inc Pirrolobenzodiazepinas y conjugados de anticuerpo-disulfuro de las mismas
CA2968447A1 (fr) 2014-11-25 2016-06-02 Adc Therapeutics Sa Conjugues anticorps-pyrrolobenzodiazepine
CN107206101B (zh) 2014-12-03 2021-06-25 基因泰克公司 季铵化合物及其抗体-药物缀合物
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201510684D0 (en) * 2015-06-17 2015-08-05 Almac Diagnostics Ltd Gene signatures predictive of metastatic disease
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP6943872B2 (ja) 2016-03-25 2021-10-06 ジェネンテック， インコーポレイテッド 多重全抗体及び抗体複合体化薬物定量化アッセイ
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
PL3458101T3 (pl) 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
CN109313200B (zh) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 用于表征位点特异性抗体-药物缀合物的生物分析性方法
JP7043425B2 (ja) 2016-06-06 2022-03-29 ジェネンテック， インコーポレイテッド シルベストロール抗体－薬物コンジュゲート及び使用方法
JP7093767B2 (ja) 2016-08-11 2022-06-30 ジェネンテック， インコーポレイテッド ピロロベンゾジアゼピンプロドラッグ及びその抗体コンジュゲート
CN110139674B (zh) 2016-10-05 2023-05-16 豪夫迈·罗氏有限公司 制备抗体药物缀合物的方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
JP6671555B2 (ja) 2017-02-08 2020-03-25 アーデーセー セラピューティクス ソシエテ アノニム ピロロベンゾジアゼピン抗体複合体
JP7247101B2 (ja) 2017-04-03 2023-03-28 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｓｔｅａｐ－１に結合する抗体
JP2020517609A (ja) 2017-04-18 2020-06-18 メディミューン リミテッド ピロロベンゾジアゼピン複合体
CA3057748A1 (fr) 2017-04-20 2018-10-25 Adc Therapeutics Sa Polytherapie avec un conjugue anticorps anti-axl-medicament
WO2018229222A1 (fr) 2017-06-14 2018-12-20 Adc Therapeutics Sa Régimes posologiques pour l'administration d'un cam anti-cd19
WO2019034764A1 (fr) 2017-08-18 2019-02-21 Medimmune Limited Conjugués de pyrrolobenzodiazépine
JP2020534300A (ja) 2017-09-20 2020-11-26 ピーエイチ・ファーマ・カンパニー・リミテッドＰｈ Ｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． タイランスタチン類似体
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
WO2020010305A1 (fr) * 2018-07-05 2020-01-09 The Board Of Regents Of The University Of Oklahoma Signatures géniques pour la caractérisation du cancer et procédés d'utilisation
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
WO2020086858A1 (fr) 2018-10-24 2020-04-30 Genentech, Inc. Inducteurs chimiques conjugués de dégradation et méthodes d'utilisation
GB201818576D0 (en) * 2018-11-14 2018-12-26 Io Biotech Aps Arginase 2 polypeptides
WO2020123275A1 (fr) 2018-12-10 2020-06-18 Genentech, Inc. Peptides de photoréticulation pour conjugaison spécifique de site à des protéines contenant fc
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995028498A1 (fr) * 1994-04-15 1995-10-26 The Trustees Of Columbia University In The City Of New York Procede de d'evaluation au niveau moleculaire des stades d'evolution du cancer de la prostate
US5858673A (en) * 1996-06-24 1999-01-12 Charlotte-Mecklenburg Hospital Authority Method for detecting prostate cells
WO1999037811A1 (fr) * 1998-01-21 1999-07-29 Urocor, Inc. Marqueurs biochimiques et cibles pour le diagnostic, le pronostic et le traitement des affections de la prostate
WO1999042622A1 (fr) * 1998-02-23 1999-08-26 Dana-Farber Cancer Institute, Inc. Procede permettant d'identifier les sites reactifs des glycosylases de reparation des mesappariements, compose et utilisations de ce dernier
WO1999064594A2 (fr) * 1998-06-11 1999-12-16 Chiron Corporation Genes et produits d'expression genique regules de façon differentielle lors du cancer de la prostate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2393618A1 (fr) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Acides nucleiques, proteines et anticorps
WO2001060860A2 (fr) * 2000-02-17 2001-08-23 Millennium Predictive Medicine, Inc. Genes, compositions, kits, et procedes d'identification, d'evaluation, de prevention, et de traitement du cancer de la prostate

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995028498A1 (fr) * 1994-04-15 1995-10-26 The Trustees Of Columbia University In The City Of New York Procede de d'evaluation au niveau moleculaire des stades d'evolution du cancer de la prostate
US5858673A (en) * 1996-06-24 1999-01-12 Charlotte-Mecklenburg Hospital Authority Method for detecting prostate cells
WO1999037811A1 (fr) * 1998-01-21 1999-07-29 Urocor, Inc. Marqueurs biochimiques et cibles pour le diagnostic, le pronostic et le traitement des affections de la prostate
WO1999042622A1 (fr) * 1998-02-23 1999-08-26 Dana-Farber Cancer Institute, Inc. Procede permettant d'identifier les sites reactifs des glycosylases de reparation des mesappariements, compose et utilisations de ce dernier
WO1999064594A2 (fr) * 1998-06-11 1999-12-16 Chiron Corporation Genes et produits d'expression genique regules de façon differentielle lors du cancer de la prostate

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CARLISLE A J ET AL: "Development of a prostate cDNA microarray and statistical gene expression analysis package", MOLECULAR CARCINOGENESIS, ALAN LISS, NEW YORK, NY,, US, vol. 28, no. 1, May 2000 (2000-05-01), pages 12 - 22, XP002225396, ISSN: 0899-1987 *
DATABASE EMBL [online] 21 November 1996 (1996-11-21), "zk91c02.s1 Soares_pregnant_uterus_NbHPU Homo sapiens cDNA clone IMAGE:490178 3', mRNA sequence.", XP002339482, retrieved from EBI accession no. EM_HUM:HSAA21266 Database accession no. HSAA21266 *
DATABASE NETAFFX [online] Affymetrix; 12 April 2006 (2006-04-12), XP002376990, retrieved from HTTPS://WWW.AFFYMETRIX.COM/ANALYSIS/NETAFFX/FULLRECORD.AFFX?PK=HUGENEFL%3AU41060_AT *
ELEK J ET AL: "MICROARRAY-BASED EXPRESSION PROFILING IN PROSTATE TUMORS", IN VIVO - INTERNATIONAL JOURNAL OF IN VIVO RESEARCH, GB, vol. 14, no. 1, January 2000 (2000-01-01), pages 173 - 182, XP001027452, ISSN: 0258-851X *
GREEN C ET AL: "Human Breast Cancer, estrogen regulated LIV-1 protein (LIV-1) mRNA, partial cds", ENTREZ NUCLEOTIDE, 6 April 1996 (1996-04-06), XP002175106 *
LADEANA HILLIER ET AL: "Generation and analysis of 280,000 human expressed sequence tags", PCR METHODS AND APPLICATIONS, COLD SPRING HARBOR, NY, US, vol. 6, no. 9, September 1996 (1996-09-01), pages 807 - 828, XP002140684, ISSN: 1054-9803 *
XU JIANGCHUN ET AL: "Identification of differentially expressed genes in human prostate cancer using subtraction and microarray", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 60, no. 6, 15 March 2000 (2000-03-15), pages 1677 - 1682, XP002198982, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
EP1474528A2 (fr) 2004-11-10
MXPA03003151A (es) 2003-08-19
JP2005506033A (ja) 2005-03-03
CA2425569A1 (fr) 2002-04-18
WO2002030268A3 (fr) 2004-08-26
WO2002030268A2 (fr) 2002-04-18
AU2002215345A1 (en) 2002-04-22

Similar Documents

Publication Publication Date Title
EP1474528A4 (fr) Procedes de diagnostic du cancer de la prostate, compositions et procedes de criblage de modulateurs du cancer de la prostate
EP1434881A4 (fr) Procedes de diagnostic du cancer, compositions et procedes de criblage de modulateurs du cancer
AU2002245317A1 (en) Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
AU3491001A (en) Compositions and methods for the early diagnosis of ovarian cancer
AU3983201A (en) Compositions and methods for the early diagnosis of ovarian cancer
HUP0203968A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2001265296A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2001249549A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
EP1515982A4 (fr) Methodes et compositions pour la therapie et le diagnostic du cancer de la prostate
AU2001231199A1 (en) Compositions and methods for the early diagnosis of ovarian cancer
AU2002347428A1 (en) Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
AU2002309583A1 (en) Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
WO2002068677A8 (fr) Nouveaux procedes de diagnostic du cancer colorectal metastatique, compositions et procedes de criblage des modulateurs du cancer colorectal metastatique
AU2001268259A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2002249871A1 (en) Novel methods of diagnosing breast cancer, compositions, and methods of screening for breast cancer modulators
AU2001269766A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
EP1317669A4 (fr) Procede de diagnostic du cancer colono-rectal et compositions et procedes de criblage de modulateurs du cancer colono-rectal
AU3752700A (en) Novel methods of diagnosing and treating breast cancer, compositions, and methods of screening for breast cancer modulators
AU2001280982A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU3755300A (en) Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
AU2002246519A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
EP1349485A4 (fr) Compositions et methodes destinees a la therapie et au diagnostic du cancer de l'ovaire
AU2001290518A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU3483001A (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2002357734A1 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030428

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20060517

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GARVAN INSTITUTE OF MEDICAL RESEARCH

17Q First examination report despatched

Effective date: 20061103

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CEDARS-SINAI MEDICAL CENTER

Owner name: GARVAN INSTITUTE OF MEDICAL RESEARCH

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ANGUS, DAVID B.

Inventor name: HEVEZI, PETER

Inventor name: AFAR, DANIEL

Inventor name: WILSON, KEITH, E.

Inventor name: MACK, DAVID, H.

Inventor name: GISH, KURT, C.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070914